» Articles » PMID: 22504293

A Pilot Comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to Predict Early Recurrence of Unifocal Hepatocellular Carcinoma After Surgical Resection

Overview
Journal Nucl Med Commun
Specialty Nuclear Medicine
Date 2012 Apr 17
PMID 22504293
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Presurgical identification of patients at high risk for early recurrence of hepatocellular carcinoma (HCC) after resection could warrant additional therapies. F-fluorodeoxyglucose (FDG) uptake by the tumour on preoperative PET can predict HCC recurrence after resection as effectively as poor differentiation or presence of microvascular invasion (MVI) on postsurgical histology. A better sensitivity for the detection of HCC nodules has been reported with F-fluorocholine (FCH), a PET tracer of lipid metabolism. This pilot study aimed to compare preoperative FDG and FCH PET/CT for predicting early recurrence of unifocal HCC, occurring within 6 months after surgical resection.

Methods: FDG and FCH tumour uptakes were assessed on preoperative PET/CT by two masked readers. On FCH PET/CT, a photopenic lesion and a hot focus were considered as indicative of malignancy. During postoperative follow-up, recurrence was searched for by regularly performing CT and MRI.

Results: In 11 consecutive HCC patients, the detection rate was greater with FCH (80%) than with FDG (27%). After resection, the overall recurrence rate was 55%. Early recurrence occurred in four patients, who were the only ones with an FDG-positive and FCH-photopenic tumour, with a significant reduction in disease-free survival. On postsurgical histology, those four patients also presented with MVI and satellite nodules. Histological differentiation and capsule disruption appeared less accurate than PET/CT or MVI in predicting early recurrence.

Conclusion: In unifocal HCC, the FCH photopenic pattern was associated with MVI and predicted early HCC recurrence after surgical resection as accurately as did an FDG uptake. Larger studies with FCH are warranted.

Citing Articles

Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma.

Nyakale N, Filippi L, Aldous C, Sathekge M Cancers (Basel). 2023; 15(7).

PMID: 37046636 PMC: 10093680. DOI: 10.3390/cancers15071975.


18F-FDG /18F-Choline Dual-Tracer PET Behavior and Tumor Differentiation in HepatoCellular Carcinoma. A Systematic Review.

Ghidaglia J, Golse N, Pascale A, Sebagh M, Besson F Front Med (Lausanne). 2022; 9:924824.

PMID: 35872754 PMC: 9300997. DOI: 10.3389/fmed.2022.924824.


Metabolism-Associated Gene Signatures for FDG Avidity on PET/CT and Prognostic Validation in Hepatocellular Carcinoma.

Lee H, Choi J, Joung J, Joh J, Kim J, Hyun S Front Oncol. 2022; 12:845900.

PMID: 35174098 PMC: 8841806. DOI: 10.3389/fonc.2022.845900.


Differential Diagnosis of Hepatic Mass with Central Scar: Focal Nodular Hyperplasia Mimicking Fibrolamellar Hepatocellular Carcinoma.

Rudolphi-Solero T, Trivino-Ibanez E, Medina-Benitez A, Fernandez-Fernandez J, Rivas-Navas D, Perez-Alonso A Diagnostics (Basel). 2022; 12(1).

PMID: 35054211 PMC: 8775045. DOI: 10.3390/diagnostics12010044.


Transcriptomics Associates Molecular Features with F-Fluorocholine PET/CT Imaging Phenotype and Its Potential Relationship to Survival in Hepatocellular Carcinoma.

Kwee S, Tiirikainen M, Sato M, Acoba J, Wei R, Jia W Cancer Res. 2019; 79(7):1696-1704.

PMID: 30760520 PMC: 6494445. DOI: 10.1158/0008-5472.CAN-18-3837.